Target- |
MechanismT lymphocyte replacements |
|
|
|
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingEarly Phase 1IIT Clinical Study on the Safety and Initial Efficacy of BGT007 Cell Therapy in Patients With Recurrent/Metastatic Refractory Digestive Tract Tumors
This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007 injection in the treatment of recurrent/metastatic/refractory digestive system tumors
/ RecruitingEarly Phase 1IIT Clinical Study on the Safety and Initial Efficacy of BGT007H Cell Therapy in Patients With Recurrent/Metastatic Refractory Digestive Tract Tumors
This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007H injection in the treatment of recurrent/metastatic/refractory digestive system tumors.
/ RecruitingEarly Phase 1IIT Clinical Study of the Safety and Initial Efficacy of BGT007 Cells in the Treatment of Patients With Relapsed /Metastatic Nasopharyngeal Carcinoma
This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma
100 Clinical Results associated with Guangzhou Bairui Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Guangzhou Bairui Biomedical Technology Co., Ltd.
100 Deals associated with Guangzhou Bairui Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Guangzhou Bairui Biomedical Technology Co., Ltd.